We strongly believe that research and development (R&D) is the cornerstone to Sihuan’s competitiveness, development and growth, hence we invest between 10% and 15% of our revenue in R&D annually to enhance R&D capabilities and enrich our product portfolio. Our level of R&D investment is well above the average of Chinese pharmaceutical companies and is close to that of the multinational pharmaceutical companies.
We carry out R&D through in-house R&D units, and also work closely with renowned research institutions, academic institutions and other pharmaceutical R&D companies in joint collaborations. In-licensing of technology or products is another way of expanding our portfolio.
Our R&D efforts cover both generic drugs as well as new chemical entities (NCEs) or patented drugs, with a clear emphasis on discovery and innovation.
